Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Narrative) (Details)

v3.20.2
Stockholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 11, 2020
Jul. 22, 2016
Jun. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Value of securities available for future issuance     $ 50,600 $ 50,600     $ 50,600      
Common stock, shares authorized     85,000,000 85,000,000     85,000,000   85,000,000  
Common stock par value (in dollars per share)     $ 0.0001 $ 0.0001     $ 0.0001   $ 0.0001  
Common stock, shares issuable     0 0     0   1,206,667  
Aggregate value of shares subscribed     $ 0 $ 0     $ 0   $ 4,923  
Common stock, shares issued     54,826,243 54,826,243     54,826,243   39,403,519  
Issuance of common shares (in shares)           29,485,000   29,485,000    
Proceeds from issuance of common shares             $ 37,230 $ 31,625    
Aggregate fees of stock issuance             $ 2,234 $ 2,140    
Predetermined offering period, lower fair market value percentage             85.00%      
Number of shares purchased under ESPP       68,351     68,351      
Shares available for future sale under ESPP     341,649 341,649     341,649      
Share-based compensation expense under ESPP       $ 200     $ 200      
Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Share of equity or debt financing used to calculate equity fee or stock issuance to maintain parity (as a percent)   2.50%                
Issuance Related to Debt Financing [Member] | Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Issuance of common shares - Founders Agreement (in shares)         31,220          
Share of equity or debt financing used to calculate equity fee or stock issuance to maintain parity (as a percent)         2.50%          
Proceeds from issuance of common shares         $ 5,000          
At the Market Offering [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Maximum value of shares authorized to sell at offering                   $ 75,000
Agent commission (as a percent)                   3.00%
Issuance of common shares (in shares)             2,100,000 3,500,000    
Share price     $ 3.76 $ 3.76   $ 6.42 $ 3.76 $ 6.42    
Proceeds from issuance of common shares             $ 8,000 $ 22,500    
Aggregate fees of stock issuance             100 500    
Proceeds from issuance of Common Stock, net of offering costs             $ 7,900 $ 22,000    
At the Market Offering [Member] | Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Issuance of common shares - Founders Agreement (in shares)     22,170              
Share of equity or debt financing used to calculate equity fee or stock issuance to maintain parity (as a percent)     2.50%              
Issuance of common shares (in shares)             53,390 87,656    
Proceeds from issuance of common shares     $ 3,000              
At the Market Offering [Member] | Fortress Biotech, Inc [Member] | Weighted Average [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Share price     $ 3.76 3.76   $ 6.42 $ 3.76 $ 6.42    
Public Offering [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Issuance of common shares (in shares) 10,769,231                  
Share price     $ 3.25 $ 3.25     $ 3.25      
Proceeds from issuance of common shares             $ 37,200      
Aggregate fees of stock issuance             2,300      
Proceeds from issuance of Common Stock, net of offering costs             $ 34,900      
Number of stock options exercised             686,373      
Public Offering [Member] | Maximum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of additional shares that can be purchased under an agreement 1,615,384                  
Public Offering [Member] | Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Issuance of common shares - Founders Agreement (in shares)     286,390              
Share of equity or debt financing used to calculate equity fee or stock issuance to maintain parity (as a percent)     2.50%              
Proceeds from issuance of common shares     $ 37,200              
Class A Common Shares [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Issuance of common shares - Founders Agreement (in shares)             0      
Number of shares converted           (137,608)   (137,608)    
Common stock, shares issued     845,385 845,385     845,385   845,385  
General and Administrative [Member] | Issuance Related to Debt Financing [Member] | Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Expenses from related party transaction         $ 100   $ 100      
General and Administrative [Member] | At the Market Offering [Member] | Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Expenses from related party transaction             100      
General and Administrative [Member] | Public Offering [Member] | Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Expenses from related party transaction             $ 900